Diversification of therapeutic targets, including intracellular and atrially-restricted channels, marks a paradigm shift toward safer and more effective anti-arrhythmic drug design.
No takes yet. Share an insight, caveat, or question.
Novel targets merit preclinical validation but should not yet guide therapy; leaves open translation to safer anti-arrhythmics in trials.
Barberini-Jammaers et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: